Neurotech embarks on ground-breaking ASD trials
Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
This much-anticipated study is being conducted under the guidance and supervision of A/Professor Michael Fahey, Head of Paediatric Neurology Monash Children’s Hospital.
It will be the first time full-spectrum <0.3% THC medicinal cannabis strains will be assessed in ASD, and NTI/DOLCE lead strain (FEN 164) will assess key behaviours in ASD over 16 weeks including a 4-week washout period (no treatment).
Neurotech’s progress in this area hasn’t gone unnoticed over the last 12 months with the company’s shares up 700% over that period.
However, a slight retracement in April may just have thrown up a useful entry point for investors looking to take advantage share price catalysts that could emerge as a result of the study.
On this note, investors can expect to receive updates throughout the course of the study, suggesting there could be near-term market sensitive news.
Platform for study established through in vitro findings
Importantly, Neurotech embarks on the study with valuable research already suggesting that the NTI/Dolce strains, with the newly discovered rarer cannabinoids CBDP and CBDB, have powerful, unique properties that extend beyond CBD alone.
For example, results that have been observed include reduced inflammation with the brain cells and increased cell health and viability.
The strains displayed more potency than using CBD isolate alone with outperformance ranging between 30% and 80%.
In terms of efficacy, the company has not observed negative effects on cell health.
Commenting on the rigorous nature of the upcoming study, Fahey said, “It is exciting to undertake a properly planned and executed study on a novel CBD product.
‘"Many other studies do not have the rigor to ensure that the results are translatable to evidence-based clinical treatments.”
Commencement of discussions with TGA
Neurotech has commenced discussions with the TGA and relevant regulatory agencies for the therapeutic expansion and registration of these novel full spectrum plants.
Studies have been designed to assess dose escalation, efficacy and a 4-week wash-out period.
All patients will be monitored and assessed by Fahey and his team which comprises senior autism/ behavioural clinical psychologists.
The company’s Mente device will also be assessed in combination with the NTI/Dolce medicinal cannabis strains.
Discussing the significance of the potential outcomes in terms of quality of life, Neurotech chairman Brian Leedman said, "This is a very exciting and novel approach to the treatment of ASD for which there is the need for safe, effective therapies with no side effects that can improve a patient’s quality of life.
"Medicinal cannabis has the potential to provide this treatment, but only NTI/DOLCE naturally derived strains offer full-spectrum CBDs with no THC, an important consideration when treating children”.
Further reading: NTI Begins Autism Clinical Trials for Unique Cannabis Strain
View Our Investment Portfolios
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction
is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
